Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
tenofovir
- Development stage
- Approved
- Lead developer
- Gilead Sciences
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Tenofovir is an antiviral medication classified as a nucleotide reverse transcriptase inhibitor (NtRTI), used primarily to treat HIV infection and chronic hepatitis B virus (HBV) infection. It is available in two main prodrug forms—tenofovir disoproxil fumarate (TDF) and tenofovir alafenamide (TAF)—which are converted in the body to the active compound, tenofovir diphosphate. This active metabolite inhibits viral reverse transcriptase and HBV polymerase by competing with natural deoxyadenosine 5'-triphosphate for incorporation into viral DNA, resulting in chain termination and prevention of viral replication. Tenofovir does not cure HIV or HBV but reduces viral load and slows disease progression[1][3][4][5][6]. It is indicated for use in adults and children as part of combination antiretroviral therapy.
- Brand names
- VireadVemlidy
- Other names
- tenofovir disoproxil fumaratetenofovir alafenamide
02
Targets
Human immunodeficiency virus type 1 reverse transcriptaseHBV Pol (Hepatitis B virus polymerase)
Beyond the preview
Go deeper on tenofovir.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on tenofovir.